Inflammation, with its associated inflammatory molecules, is integral to most chronic diseases, including the various cardiovascular diseases. Interleukin 12 (IL12) is one of the inflammatory cytokines that is upregulated during inflammation; however, we know very little about its exact effect on red blood cells (RBCs), platelets and fibrin(ogen). IL12 is an important pleiotropic cytokine in early inflammatory responses and has potent immunomodulatory, antitumour and anti-infection activity. Here we investigate how low levels of circulating IL12, comparable to levels found during chronic inflammation, affect coagulation parameters, platelets and RBCs. We used thromboelastography, scanning electron microscopy, refractometery and wide-field microscopy. Our results show that IL12 caused hypercoagulation, platelet activation and spreading, as well as RBC agglutination. This phenomenon has far-reaching implications for treatment of the plethora of conditions where IL12 is upregulated, since it suggests aberrant haemorheology as agglutination affects blood flow. This information might be used in future to target the lowering of IL12 in inflammatory conditions, as well as address RBC agglutination.
Inflammation, with its associated inflammatory molecules, is integral to most chronic diseases, including the various cardiovascular diseases. The inflammatory response is characterised by various upregulated cytokines and molecules that are immunomodulatory and have pathophysiological importance. However, the inflammatory stimulus is often unknown. Moreover, the understanding of how individual cytokines are involved in inflammatory signalling and how individual molecules affect various individual cell types are also largely unknown. Understanding individual inflammatory marker signalling may therefore be of interest in therapeutic targeting of inflammation. As upregulated inflammatory molecules are circulating, they have a direct and powerful effect on the haematological system, not only on the immune cells, but also on erythrocytes (RBCs), platelets and the plasma protein fibrin(ogen). One of the hallmarks of inflammation is a pathological coagulation system, and this is the direct result of upregulated circulating inflammatory molecules. During inflammation, platelets become aggregated and activated, with microparticle formation; RBCs become eryptotic and also produce microparticles (Van Der Spuy & Pretorius, 2013; Gasparyan et al, 2014; Pretorius & Kell, 2014; Pretorius et al, 2016a,c; Soma et al, 2016) ; and pathological plasma clots form, mainly due to pathological changes in the healthy fibrin (ogen) protein structure Pretorius et al, 2016b) . Therefore, by studying the effect of individual inflammatory molecules on RBCs, platelets and fibrin(ogen) we may improve our understanding of the inflammatory response and provide important advances in understanding both inflammation regulation and the resulting pathophysiological coagulation.
Interleukin 12 (IL12) is one of the inflammatory cytokines that is upregulated during inflammation; however, we know very little about its exact effect on RBCs, platelets and fibrin (ogen). IL12 is an important pleiotropic cytokine in early inflammatory responses and has potent immunomodulatory, anti-tumour, and anti-infection activity in vitro and in vivo (Wang et al, 2012; Taylor-Fishwick et al, 2013; Tsai et al, 2014; Sun et al, 2015) . The IL12 family contains the only heterodimeric cytokines, and it includes IL12, IL23, IL27 and IL35; consisting of an a-chain (p19, p28 or p35) and a bchain (p40 or Ebi3) (Vignali & Kuchroo, 2012; Behzadi et al, 2016) . IL12 consists of (p35/p40) (Jana & Pahan, 2009; Gverovi c et al, 2012; Jones et al, 2012; Skrombolas et al, 2015) and signals via IL12Rb1 and IL12Rb2 receptors (Delgoffe et al, 2011; de Paus et al, 2013; Wei et al, 2015) . Ligation of IL12 to its receptor involves the binding of IL12p35 to IL12Rb2 and IL12p40 to IL12Rb1 (de Paus et al, 2013) . After ligation, signalling is mediated via the Janus kinase-signal transducers and activators of transcription (JAK-STAT) family (Delgoffe et al, 2011; Vignali & Kuchroo, 2012) . IL12 ligation results in the activation of tyrosine kinase 2 (TYK2), which is associated with the IL12Rb1 chain, and Janus kinase 2 (JAK2), which is associated with the IL12Rb2 chain (de Paus et al, 2013) . Activation of both TYK2 and JAK2 direct the phosphorylation of STAT4, followed by STAT4 being dimerised and finally transported to the nucleus, where it acts as a transcription factor (Delgoffe et al, 2011; de Paus et al, 2013 2013) . It is known that IL12 acts through STAT4 to induce IFN-c production in T and NK cells (Zundler & Neurath, 2015) . IL12 is therefore an important circulating marker of inflammation, together with others, including TNF-a, IL1b, IFN-c, IL6, IL8, IL10, and also markers such as tissue factor and plasminogen activator inhibitor (PAI)-1, which drive hypercoagulation (Bastarache et al, 2012) . Upregulated IL12 has been found in various inflammatory conditions, including sarcoidosis (Shigehara et al, 2003) , coronary artery disease (Wegner et al, 2008) , periodontitis (Robati et al, 2011) , chronic liver failure (Liu et al, 2011) , cardiovascular diseases and atherosclerosis (Weyand & Goronzy, 2013; Yong et al, 2013a,b; Nikolajuk et al, 2015) . It is also upregulated in type 2 diabetes (T2D) (Gverovi c et al, 2012) ; in particular, T2D individuals with higher insulin resistance and abnormal lipids exhibit elevated IL12, endothelial dysfunction and proinflammatory markers (Mishra et al, 2011) .
A literature search showed that IL12 levels in various diseases compared to the levels in healthy individuals are:
• In healthy individuals: 84Á3 AE 10Á6 pg/ml (Tian & Kang, 2014) ; 124Á94 AE 77Á89 pg/ml (Gverovi c et al, 2012); 101Á67 AE 11Á70 pg/ml (Robati et al, 2011) .
• Mean serum levels in T2D: 141Á63Á1 AE 91Á24 pg/ml (Gverovi c et al, 2012 ).
• Periodontitis: 125Á08 AE 19Á85 pg/ml (Robati et al, 2011) .
• Chronic liver failure: 217Á16 AE 70Á97 pg/ml survival vs.
289Á38 AE 89Á17 pg/ml death vs. 45Á20 AE 20Á06 pg/ml in controls (Liu et al, 2011 ).
• The levels of serum IL12 p40 in patients with sarcoidosis:
1080 AE 136 pg/ml vs. controls 331 AE 34Á4 pg/ml (Shigehara et al, 2003) .
IL12 is therefore implicated as one of the major roleplayers in inflammation and has been identified as a proinflammatory cytokine. Inflammation and hypercoagulation are stalwart associates, and, at the least, demonstrate an extremely common co-existence in many circumstances. Indeed, in all the above-mentioned conditions, hypercoagulation is a known indicator of the disease; e.g. sarcoidosis (Hasday et al, 1988; Nakstad et al, 1990) , T2D (Tripodi et al, 2011; Pretorius et al, 2013 Pretorius et al, , 2015 , coronary artery disease (Tantry et al, 2010; Reddel et al, 2013) , chronic liver disease (Lisman et al, 2010) and periodontitis (Tonetti & Van Dyke, 2013) . In addition, IL12 is thought to contribute to the development of atherosclerosis (Wegner et al, 2008) .
We already know that IL12 is closely linked to the activities of T and NK cells and that its upregulation occurs concomitantly with a general upregulated cytokine profile cocktail. However, the question that now arises is, how does it specifically affect coagulation and other cells of the haematological system. A literature search could not establish the presence of the IL12 receptors IL12Rb1 and IL12Rb2 on either RBCs or platelets and very little information on how it affects coagulation is available (Portielje et al, 2001) .
After taking all the evidence into consideration, we note that there is no research that we could find that specifically looks at the individual effect of IL12 on RBCs, platelets, and plasma proteins, specifically fibrin(ogen). Our hypothesis, therefore, is that low levels of circulating IL12, comparable to levels found during chronic (low-grade) inflammation, may cause hypercoagulation and associated changes to the cells of the haematological system, such as activated platelets and eryptotic RBCs (programmed cell death in RBCs). Our research tools were thromboelastography, scanning electron microscopy, refractometery and wide-field microscopy.
Materials and methods

Study design
This controlled laboratory experiment aimed to determine the effect of IL12, at levels characteristic of low-grade chronic inflammation, on human RBCs, platelets and fibrin(ogen). This study was approved by the Ethical Committees of the University of Pretoria and Stellenbosch University (South Africa) (N17/01/008_RECIP_UP.298/2016). A written form of informed consent was obtained from all healthy donors (available on request). Blood was collected and methods were carried out in accordance with the relevant guidelines of the ethics committee (ethics number: 298/2016: E Pretorius and J Bester: principal investigators for use of control blood). We adhered strictly to the Declaration of Helsinki.
Blood was collected in citrate tubes by a qualified phlebotomist. Collected blood was at left at room temperature for 30 min to allow the citrate to act on calcium, followed by experimentation. Treated samples were exposed to IL12 for 10 min before experimentation. All whole blood (WB) experiments were concluded within 5 h of collection. We have previously established that thromboelastography (TEG) and scanning electron microscopy (SEM) experiments give repeatable results when left at room temperature for a maximum of 24 h (Pretorius et al, 2017) . However, experiments carried out within 6 h of collection are optimal. Platelet poor plasma (PPP) was prepared after the 30-min standing period and stored at À80°C until the day of the experiment. Blinded analysis was conducted using healthy blood samples before and after exposure to IL12.
Healthy volunteer details and blood collection
Blood samples were obtained from 14 healthy individuals with no known inflammatory condition or use of any chronic medication, and who did not smoke or, if female, use contraception. Their ages ranged from 18 to 62 years (median: 26 AE 12).
Concentration of IL12 used
Concentrations of IL12 are mostly measured in either plasma or serum. We exposed healthy WB and PPP to a final IL12 exposure concentration of 100 pg/ml for 10 min at room temperature, as this concentration is in line with IL12 concentrations found in plasma and serum of systemic chronic inflammation (see introduction). IL12 was purchased (from Sigma-Aldrich South Africa: Johannesburg, South Africa; catalogue number: SRP3073) as a lyophilized powder and reconstituted in phosphate-buffered saline (PBS). Recombinant human IL12 is a 75 kDa heterodimeric glycoprotein consisting of disulfide-linked 35 kDa (p35) and 40 kDa (p40) subunits (503 total amino acid residues).
Thromboelastography of whole blood and platelet poor plasma: clot property studies Whole blood (WB) was collected in citrate tubes and then left at room temperature for 30 min. After this time, samples were prepared by either incubating WB with IL12 for 10 min or leaving the sample untreated (na€ ıve sample). PPP was prepared by centrifuging WB for 15 min at 3000 g. All samples were stored at À80°C until the day of experiment. PPP was restored to room temperature, followed by the same sample preparation and incubation as for WB above. Clot property studies using TEG (Thromboelastograph 5000 Hemostasis Analyzer System; Haemonetics S.A. Signy-Avenex, Switzerland) were performed with both WB and PPP as follows: 340 ll of na€ ıve or treated WB or PPP were placed in a TEG cup to which 20 ll of 0Á2 mol/l CaCl 2 was added. CaCl 2 is necessary to reverse the effect of the sodium citrate anticoagulant in the collection tube and consequently initiate coagulation. The samples were then loaded in the TEG for analysis.
A maintenance check was performed at the start of every day to ensure that the TEG channels were in equilibrium, and a two-stage quality control service was conducted regularly, when notified by the system after 50 runs in each channel. We ran the na€ ıve sample, followed by the corresponding exposed sample, as consecutive runs in the same TEG channel. These checks served to limit intra-and inter-assay variability.
Platelet poor plasma refractometry
Refractometry is the analytical method of measuring the refractive index (RI) of a fluid. An aliquot (10 ll) of PPP with or without exposure to IL12 was analysed using the Atagoâ clinical refractometer (Chembiz, Capetown, South Africa). This is a manual measuring tool and it does not require user calibration.
Wide-field microscopy of whole blood using the Zeiss CellDiscoverer 7
We used wide-field microscopy and autofluorescence of RBC to study the effect of addition of IL12 to WB. Images were acquired with the CellDiscoverer 7 (Zeiss, Oberkochen, Germany) using a combination of three light-emitting diode (LED) modules simultaneously: 385, 470 and 567 nm wavelengths. The following bandpass emission filters were used: 412-438; 501-527 and 583-601. Plan Apochromat 509/ 1Á2NA (Zeiss) with a 29 tube lens were used with an Axiocam 506 mono-camera (Zeiss). WB (90 ll) was added to a plate, and images taken of the na€ ıve WB. We then added 10 ll of IL12 (final exposure concentration of 100 pg/ml) followed by stabilising the WB and capturing images at 2 and 4 min after IL12 exposure.
Scanning electron microscopy of whole blood WB was incubated for 10 min with IL12, as described above. Na€ ıve or exposed WB (10 ll) was placed on a glass cover slip and smears were prepared for SEM analysis. Briefly, WB smears were washed in PBS, fixed in 4% formaldehyde and 1% osmium tetraoxide before being dehydrated in increasing grades of ethanol and hexamethyldisilazane [for detailed methods, see Bester and Pretorius (2016) , Pretorius et al (2017) ]. Micrographs of both WB smears were taken using a Zeiss cross beam electron microscope and Merlin (Gemini 2). Micrographs of WB smears were taken to study the ultrastructure of the both platelets and RBCs, with specific focus on their membranes.
Statistical analysis
TEG and refractive index results were analysed with the StatsDirect (version 2.8.0) software (StatsDirect Ltd, Cheshire, UK). The Shapiro-Wilk test was used to assess normality. For normally distributed data, we used the paired t-test, whereas the Mann-Whitney test was used for non-normally distributed data. The significance was taken as P ≤ 0Á05.
Results
Thromoelastography of whole blood and platelet poor plasma
Results from WB TEG analysis showed clot properties due to both the cellular (platelets and RBC) components, as well as the plasma protein components (Pretorius et al, 2017) . Whole blood TEG parameters are also affected by immune cell contributions. On the other hand, PPP clot results show only the effect of the plasma proteins, which mostly consists of fibrin(ogen). Seven parameters, as shown in Table I , were studied de Villiers et al, 2015; Pretorius et al, 2017) . Table II shows sample demographics and TEG results for both WB and PPP before and after exposure to IL12. All WB parameters were normally distributed and assessed by the paired t-test. For PPP, the K, MRTG, TMRTG and TTG were not normally distributed and assessed using the Mann-Whitney test. Four WB TEG parameters showed significant changes after addition of IL12. While the R-time (clot initiation time to 2 mm) did not change significantly, the K-value (initiation time to 20 mm) decreased. This suggests that both na€ ıve WB and na€ ıve WB with added IL12 take approximately the same time to commence clot formation; however, overall, the clot reaches the set amplitude (K) slower. The MA (clot strength as overall stability), MRTG (maximum velocity of clot growth) and the TGG (clot strength as total clot resistance) are all significantly increased. When assessing clot propagation using the changes in elastic modus over time, it is a better parametric evaluation to use MRTG instead of the angle. Here, added IL12 caused a significant change in MRTG; this change represents the first derivative of the velocity of the increase in clot strength (Nielsen et al, 2004; Sousa et al, 2016) . Taken together, this suggests that the presence of IL12 causes a hypercoagulable clot formation. The results of healthy PPP with and without added IL12 did not show any significant changes. However, the tendencies of the parameters are similar to that of the WB results. From the WB and PPP TEG analysis, we suggest that pathophysiological changes in the presence of IL12, to the formed elements of WB (platelets and RBCs), may be the main cause of the clot hypercoagulability.
Platelet poor plasma refractometry
The refractive index (RI) of serum or plasma depends mainly upon its protein concentration (one of their fundamental physical properties), and has in the past been used to study differences in healthy versus diseased blood (Reddy et al, 2012) . There was a significant difference between the RI of na€ ıve versus IL12-exposed PPP (P < 0Á0001), and the addition of IL12 decreased the RI of PPP in all 10 healthy PPP samples. This suggests that IL12 affects the plasma protein packaging, which may be partly responsible for the slight changes towards a more hypercoagulable clot, as noted in some of the PPP TEG parameters.
Wide-field microscopy using the Zeiss CellDiscoverer 7
Previously we have shown that, in the presence of IL1b, IL6 and IL8, RBCs become eryptotic . The maximum velocity of clot growth observed or maximum rate of thrombus generation using G, where G is the elastic modulus strength of the thrombus in dynes per cm The CellDiscoverer 7 enabled us to acquire images before and shortly after the addition of IL12. Figure 1 shows images of WB before addition of IL12 (A) and 2 min after IL12 exposure (B). Images show only RBC autofluorescence. The morphology of the RBCs changed rapidly after addition of IL12. However, the changes cannot be well-described at this resolution. Therefore, we sought to investigate the ultrastructure using electron microscopy.
Scanning electron microscopy of whole blood
Figures 2 and 3 show SEM analysis of WB with platelets and RBCs. In control WB smears, RBCs mostly lie separated from each other and platelets show only slight pseudopodia formation due to contact activation (Fig 2) . After the addition of IL12, RBC agglutination was visible in all our samples (Fig 3) . Furthermore, platelet activation and spreading were also noted, and interactions between these activated platelets and agglutinated RBCs were frequently observed. While electron microscopy does allow for the identification of the immune cells by using nucleus shape, transmission microscopy would mostly be utilized for this, and not SEM. Also, the focus of this paper was not on immune cells. However, it is noted that neutrophils themselves produce IL12 (Balderramas et al, 2014) , and that effects on the immune cells could be a contributing factor to the changes observed in blood cells.
Discussion
IL12 is one of the dysregulated cytokines noted frequently in different inflammatory conditions. Previously we have shown that IL1b, IL6 and IL8, at low physiological levels, representative of chronic inflammation, caused significant changes in the viscoelastic properties of WB to display an increased hypercoagulability . We saw a significant change in platelet structure, where all three cytokines caused platelet hyper-activation and spreading. RBC structure Demographic data of healthy individuals N = 14. Age = 26 AE 12 years Na€ ıve (n = 11) IL12 (n = 11) P-value TEG results for na€ ıve whole blood exposed to IL12 for 10 min at room temperature
565Á72 AE 128Á07 664Á04 AE 161Á99 0Á025 TEG results for na€ ıve platelet poor plasma exposed to IL12 for 10 min at room temperature
Bold, significant P-values taken as P ≤ 0.05; Italics, indicate non-parametric assessments using the Mann-Whitney analysis infection activity in vitro and in vivo (Wang et al, 2012; Taylor-Fishwick et al, 2013; Tsai et al, 2014; Sun et al, 2015) . Agglutination occurs mostly during infection and RBC adhesion is known to be abnormal in e.g. type 2 diabetes, correlating to vascular complications and thrombosis (Wautier & Wautier, 2004) . Considering this, the impact of agglutination in cardiovascular disease and inflammation might be of importance. This agglutination, as well as an increased platelet hyperactivation, may be the cause of the hypercoagulability noted in TEG, where four of the TEG parameters pointed to increased hypercoagulation. PPP did not show a significantly increased hypercoagulation in the presence of IL12, however, we observed a procoagulant trend in some of the parameters that were significantly changed in the WB TEG. The RI of PPP in all the controls were decreased significantly, suggesting a changed plasma protein packaging. This may be in part responsible for the slight changes towards a more hypercoagulable clot, as noted in the PPP TEG parameters. This change may also be responsible for the agglutination of the RBCs in WB.
The cell membranes of RBCs show a complex rheological response with viscoelastic behaviour. Therefore, flow and deformation behaviour of blood and its formed elements contributes significantly to haemorheology (Sousa et al, 2016) . In addition, the haematological system, including plasma proteins, are particularly sensitive to systemic inflammatory changes. Determination of the ultrastructure and function of this system in the presence of individual inflammatory molecules, such as IL12, provide a better understanding of inflammatory conditions, and the biophysical data discussed in this paper may in future be applied in therapeutic studies. This phenomenon has far-reaching implications for treatment of the plethora of conditions where these cytokines are upregulated, as it suggests a condition of aberrant haemorheology, as agglutination affects blood flow.
The results presented here and in a previous paper, where we looked at the effects of IL1b, IL6 and IL8 on RBCs structure and coagulation parameters , suggest that the actions of the various individual cytokines specifically on the RBC structure, varies significantly. Various cytokines are dysregulated in inflammatory conditions, with an altered cytokine profile being an important characteristic of many diseases. Even though the overall profile is fundamental to the disease, elucidating the effects of the profile constituents may be very useful for integrating the complexity of the profile. Thus, this information might be used in future to target the lowering of IL12 in inflammatory conditions. Future research should however, include larger sample sizes and the long-term effect of increased IL12 levels, might also be of interest.
